DIPROLENE AF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIPROLENE AF (DIPROLENE AF).
Betamethasone dipropionate is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of phospholipase A2, thereby reducing the release of arachidonic acid and subsequent production of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Primarily hepatic via CYP3A4; undergoes glucuronidation and sulfation. |
| Excretion | Primarily hepatic metabolism; inactive metabolites excreted renally (approximately 80-85% as metabolites in urine) and fecally (approximately 15-20%). |
| Half-life | Approximately 2.5-3 hours (terminal half-life) for betamethasone dipropionate (active moiety); clinical effects persist beyond half-life due to receptor-mediated activity. |
| Protein binding | Approximately 64-70% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Not well characterized for topical formulation; systemic Vd for betamethasone is approximately 0.6-1.4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Systemic absorption is low (approximately 7-15% of applied dose) through intact skin; absorption increases with occlusive dressings, inflamed skin, or prolonged use. |
| Onset of Action | Topical: 2-3 days for measurable clinical improvement in inflammatory dermatoses. |
| Duration of Action | Topical: Once-daily application maintains effect for 24 hours; clinical improvement sustained with continued use. |
| Molecular Weight | 504.6 |
Apply a thin film to affected skin areas twice daily. Maximum 45 g per week. Not to exceed 2 consecutive weeks of treatment.
| Dosage form | CREAM, AUGMENTED |
| Renal impairment | No dosage adjustment required for renal impairment. Systemic absorption is minimal when used topically. |
| Liver impairment | No specific recommendations for hepatic impairment. Caution in severe hepatic impairment due to potential for increased systemic absorption. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. Use not recommended in children under 12 years of age due to higher skin surface-to-body weight ratio increasing risk of systemic adverse effects. For children 12 years and older, follow adult dosing with caution, limited to shortest duration possible. |
| Geriatric use | Use with caution in elderly patients due to age-related skin thinning and potential for increased systemic absorption. Limit duration and area of application to minimize risk of local and systemic adverse effects. |
| 1st trimester | Avoid use during first trimester due to risk of teratogenicity; use only if clearly needed and benefit outweighs risk. |
| 2nd trimester | Use with caution; may cause fetal growth restriction and adrenal suppression. Use minimal effective dose and shortest duration. |
| 3rd trimester | Avoid prolonged use; risk of fetal adrenal suppression and low birth weight. Discontinue if preterm labor. |
Clinical note
Comprehensive clinical and safety monograph for DIPROLENE AF (DIPROLENE AF).
| Placental transfer | Betamethasone crosses the placenta; systemic exposure after topical application is low but may be significant with extensive use or occlusive dressings. |
| Breastfeeding | Topical corticosteroids, including betamethasone dipropionate, are considered generally compatible with breastfeeding when used on small areas for short periods. Avoid application to breasts or nipples to prevent infant ingestion. Monitor infant for potential adrenal suppression if large areas or prolonged use. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to betamethasone dipropionate or any component of the formulationViral, fungal, or bacterial skin infections (untreated)Perioral dermatitisRosacea
| Precautions | Reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, skin atrophy, striae, telangiectasias, potential for systemic effects if applied to large body surface areas or occlusive dressings, exacerbation of infections, delayed wound healing, perioral dermatitis, allergic contact dermatitis, posterior subcapsular cataracts, glaucoma. |
| Food/Dietary | No known food interactions. Take with or without food as needed. |
Loading safety data…
| Lactation Rating | L2 - Limited data - probably compatible |
| Teratogenic Risk | Corticosteroids cross the placenta. First trimester: Increased risk of cleft palate (odds ratio 3.4) based on observational studies. Second/third trimester: Risk of fetal adrenal suppression, low birth weight, and preterm birth with prolonged high-dose systemic use. Topical application (including augmented betamethasone) has minimal systemic absorption; however, large areas, occlusion, or broken skin may increase risk. Avoid high-potency steroids on face, flexures, or during pregnancy unless necessary. |
| Fetal Monitoring | Monitor for maternal skin atrophy, striae, or infection at application site. In prolonged high-dose use or large body surface area applications, consider periodic assessment of maternal blood pressure, blood glucose, and growth ultrasound for fetal growth restriction. No routine drug level monitoring required. |
| Fertility Effects | No specific studies on Diprolene AF and fertility. Systemic corticosteroids may cause menstrual irregularities or ovulatory dysfunction at high doses. Topical application with minimal systemic absorption is unlikely to impair fertility. No evidence of adverse effects on spermatogenesis from topical use. |
| Clinical Pearls |
| DIPROLENE AF (augmented betamethasone dipropionate 0.05%) is a super-high potency topical corticosteroid. Use no more than 50 g per week; limit continuous treatment to 2 weeks. Avoid on face, groin, axillae, and intertriginous areas due to increased risk of striae, atrophy, and telangiectasias. Do not use with occlusive dressings unless directed; occlusion increases systemic absorption. Monitor for HPA axis suppression with large doses or prolonged use. Not for pediatric patients under 12 years or for atopic dermatitis in children due to high potency. |
| Patient Advice | Apply a thin layer to the affected skin only, once or twice daily as directed. · Do not use on the face, underarms, or groin unless specifically instructed by your doctor. · Wash your hands after applying, unless treating the hands. · Do not cover the treated area with bandages or wraps unless told to do so by your doctor. · Do not use for longer than prescribed; usually no more than 2 continuous weeks. · Avoid contact with eyes; if contact occurs, rinse with water. · Inform your doctor if you develop severe skin irritation, signs of allergic reaction, or if condition worsens or does not improve after 2 weeks. · Do not use this medication for other skin conditions or share it with others. |